Table 1.
Characteristics of SNPs used as instruments to proxy drug targets
| SNP | EA/NEA | EAF | Effect (SE) T2D | p value T2D | Effect (SE) HbA1c |
|---|---|---|---|---|---|
| ABCC8 | |||||
| rs5219 | C/T | 0.63 | –0.069 (0.005) | 3.15×10−48 | –0.016 (0.002) |
| rs4148640 | T/G | 0.27 | –0.045 (0.007) | 4.47×10−11 | –0.009 (0.002) |
| rs61880293 | T/C | 0.92 | –0.058 (0.009) | 8.13×10−10 | –0.015 (0.004) |
| rs7130826 | T/G | 0.73 | –0.031 (0.005) | 1.94×10−9 | –0.004 (0.002) |
| rs10832783 | G/A | 0.92 | –0.055 (0.009) | 4.63×10−9 | –0.011 (0.004) |
| rs214080 | A/G | 0.41 | –0.026 (0.005) | 1.96×10−8 | –0.007 (0.002) |
| GLP1R | |||||
| rs10305420 | T/C | 0.38 | –0.032 (0.005) | 2.69×10−11 | –0.011 (0.002) |
| rs34179517 | A/C | 0.87 | –0.044 (0.007) | 3.09×10−10 | –0.007 (0.003) |
| rs9296291 | C/T | 0.23 | –0.033 (0.006) | 3.42×10−9 | –0.013 (0.002) |
| rs10305457 | C/T | 0.90 | –0.044 (0.008) | 3.04×10−8 | –0.018 (0.003) |
| PPARG | |||||
| rs7637403 | A/G | 0.11 | –0.074 (0.007) | 1.03×10−24 | –0.007 (0.003) |
| rs4135247 | A/G | 0.57 | –0.042 (0.005) | 2.23×10−19 | –0.035 (0.002) |
| rs598747 | A/G | 0.84 | –0.052 (0.007) | 9.51×10−15 | –0.022 (0.003) |
| rs150535373 | A/G | 0.02 | –0.140 (0.019) | 5.38×10−13 | –0.005 (0.009) |
| rs143888770 | T/C | 0.02 | –0.106 (0.016) | 1.21×10−10 | –0.015 (0.007) |
| rs17819328 | T/G | 0.58 | –0.028 (0.005) | 9.56×10−10 | –0.023 (0.002) |
| rs4135300 | C/T | 0.89 | –0.045 (0.008) | 5.50×10−9 | –0.013 (0.003) |
Effect (SE) corresponds to change in loge (OR) of type 2 diabetes or change in IRNT HbA1c (mmol/mol)
p value corresponds to type 2 diabetes analyses
EA, effect allele; EAF, effect allele frequency; NEA, non-effect allele; T2D, type 2 diabetes